Spondyloarthritis & psoriatic arthritis
Factors associated with COVID-19 severity in patients with spondyloarthritis: Results of the French rheumatic and musculoskeletal disease (RMD) COVID-19 cohort
Authors' conclusion
In this study, the majority of patients with SpA had a favorable COVID-19 outcome. We confirmed age and corticosteroids therapy had a negative impact on disease outcomes while TNFi use was protective.
Study context
- Population
- Patients with spondyloarthritis (SpA) and COVID-19 from the French national multicentre RMD COVID-19 cohort (56% female, mean age 49±14 years)
- Participants
- 626 patients
- Exposure
- Mild vs Moderate vs Severe
- Mildn = 508
- Moderaten = 93
- Severen = 25
- Outcome
- COVID-19 characteristics by severity (mild, moderate or severe), serious infection including moderate and severe cases
Methodological detailsnational multicentre
- National multicentre
Main finding
As reported in the abstract
COVID-19 severity
- Clinical signs and symptoms of COVID-19
- 587 (94%)
- Fever
- 63%
- Cough
- 62%
- Flu-like symptoms
- 53%
- Agueusia
- 39%
- Anosmia
- 37%
- Dyspnea
- 32%
- Diarrhea
- 19.9%
Observational data: associations, not effects.
Secondary outcomes
Factors associated with COVID-19 severity
| OR (95% CI) | P value | ||
|---|---|---|---|
| Corticosteroid therapy | 3.08 (1.44–6.58) | P = 0.004 | |
| Age | 1.06 (1.04–1.08) | P < 0.001 | |
| TNFi useAssociated with less severe disease | 0.27 (0.09–0.78) | P = 0.01 | |
| 0.050.21520Odds ratio (log scale) |
- No association identified between NSAID use and COVID-19 severity
Original publication
Factors associated with COVID-19 severity in patients with spondyloarthritis: Results of the French RMD COVID-19 cohort. Joint Bone Spine. Published 5 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →